Spike (alpha B.1.1.7 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)

Spike (alpha B.1.1.7 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)
Spike (alpha B.1.1.7 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)
   
COVID-19 Forschung
Artikelnummer Größe Datenblatt Manual SDB Lieferzeit Menge Preis
BPS-78158-1 100 µl - -

3 - 15 Werktage*

1.223,00 €
BPS-78158-2 1 ml (500 µl x 2) - -

3 - 15 Werktage*

5.762,00 €
 
The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome... mehr
Produktinformationen "Spike (alpha B.1.1.7 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)"
The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. The United Kingdom (UK) identified a variant called B.1.1.7 with a large number of mutations in the fall of 2020. This variant spreads more easily and quickly than other variants. The Spike (B.1.1.7 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.1.7 variant Spike (Genbank Accession #QHD43416.1 with B.1.1.7 variant mutations, see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the enhanced green fluorescent protein (eGFP) gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP fluorescence. The Spike (B.1.1.7 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.7 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.1.7 variant Deletions of H69, V70, and Y144 N501Y A570D D614G P681H T716I S982A D118H
Schlagworte: 2,
Hersteller: BPS Bioscience
Hersteller-Nr: 78158

Eigenschaften

Anwendung: Viral transduction studies, neutralizing antibody screening
Spezies-Reaktivität: SARS-CoV-2

Handhabung & Sicherheit

Lagerung: -80°C (avoid repeat freezing and thawing cycles)
Versand: -80°C (International: °C)
Achtung
Nur für Forschungszwecke und Laboruntersuchungen: Nicht für die Anwendung im oder am Menschen!
Hier kriegen Sie ein Zertifikat
oder , um Analysenzertifikate anzufordern.
Bewertungen lesen, schreiben und diskutieren... mehr
Kundenbewertungen für "Spike (alpha B.1.1.7 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)"
Bewertung schreiben
oder , um eine Produktbewertung abzugeben.
Zuletzt angesehen